EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Bile salt signaling and bile salt-based therapies in cardiometabolic disease

Claire C J Groenen, Thuc-Anh Nguyen, Coen C Paulusma, Stan F J van de Graaf iD

Clinical Science · 10.01.2024 · 138 (1) · 1-21

DOI: 10.1042/cs20230934 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Science, online erschienen am 05.01.2024. Verfasst von Claire C J Groenen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Tytgat Institute for Liver and Intestinal Research, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Fatty Liver, Cardiovascular Diseases. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 184 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bile salts have an established role in the emulsification and intestinal absorption of dietary lipids, and their homeostasis is tightly controlled by various transporters and regulators in the enterohepatic circulation. Notably, emerging evidence points toward bile salts as major modulators of cardiometabolic disease (CMD), an umbrella disease of disorders affecting the heart and blood vessels that is caused by systemic metabolic diseases such as Type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatotic liver disease (MASLD), the latter encompassing also metabolic dysfunction-associated steatohepatitis (MASH). The underlying mechanisms of protective effects of bile salts are their hormonal properties, enabling them to exert versatile metabolic effects by activating various bile salt-responsive signaling receptors with the nuclear farnesoid X receptor (FXR) and the Takeda G-protein-coupled receptor 5 (TGR5) as most extensively investigated. Activation of FXR and TGR5 is involved in the regulation of glucose, lipid and energy metabolism, and inflammation. Bile salt-based therapies directly targeting FXR and TGR5 signaling have been evaluated for their therapeutic potential in CMD. More recently, therapeutics targeting bile salt transporters thereby modulating bile salt localization, dynamics, and signaling, have been developed and evaluated in CMD. Here, we discuss the current knowledge on the contribution of bile salt signaling in the pathogenesis of CMD and the potential of bile salt-based therapies for the treatment of CMD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Fatty LiverCardiovascular DiseasesHumansSignal TransductionBile Acids and SaltsEnergy MetabolismMembrane Transport Proteins

Stichwörter der Autor:innen

ASBTBile acidNTCPatherosclerosis

Substanzen

Bile Acids and SaltsMembrane Transport Proteins

Autor:innen und Institutionen

  • Tytgat Institute for Liver and Intestinal Research, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
  • Amsterdam Gastroenterology, Endocrinology and Metabolism (AGEM), Amsterdam University Medical Centers, The Netherlands.

ORCID-Profile: Stan F J van de Graaf

Förderung

  • Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO)

Zitieren

APA

Groenen, C. C. J., Nguyen, T. A., Paulusma, C. C., & van de Graaf, S. F. J. (2024). Bile salt signaling and bile salt-based therapies in cardiometabolic disease. Clinical Science, 138(1), 1-21. https://doi.org/10.1042/cs20230934

Vancouver

Groenen CCJ, Nguyen TA, Paulusma CC, van de Graaf SFJ. Bile salt signaling and bile salt-based therapies in cardiometabolic disease. Clinical Science. 2024;138(1):1-21. doi:10.1042/cs20230934

BibTeX
@article{Groenen2024,
  author = {Groenen, Claire C J and Nguyen, Thuc-Anh and Paulusma, Coen C and van de Graaf, Stan F J},
  title = {Bile salt signaling and bile salt-based therapies in cardiometabolic disease},
  journal = {Clinical Science},
  year = {2024},
  volume = {138},
  number = {1},
  pages = {1--21},
  doi = {10.1042/cs20230934}
}
Kostenlos starten →